×

Zafgen to Present at Canaccord Genuity’s 36th Annual Growth Conference

BOSTON, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that Thomas Hughes, President and Chief Executive Officer of Zafgen, will present at the upcoming Canaccord Genuity 36th Annual Growth Conference in Boston on Wednesday, August 10, 2016 at 5:00 p.m. ET.

A live audio webcast and replay of the presentation will be available through the Events and Presentations page of the Investors section of the Company's website (www.zafgen.com) for 90 days following the conclusion of the live event.

About Zafgen

Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms of severe and complicated obesity through the MetAP2 pathway. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare forms of obesity. Zafgen's lead product candidate is ZGN-1061, which is a novel, first-in-class, twice-weekly subcutaneous injection which is being developed for the treatment of severe and complicated obesity. Zafgen is also developing ZGN-839, a liver-targeted MetAP2 inhibitor, for the treatment of nonalcoholic steatohepatitis, or NASH, and abdominal obesity. Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients affected by metabolic diseases.


Investor Relations Contact: Argot Partners Investor Relations Laura Perry or Glenn Garmont 212-600-1902 laura@argotpartners.com glenn@argotpartners.com

Source:Zafgen, Inc.